Malignant vascular tumors-an update

Modern Pathology

Volumn 27, Issue SUPPL. 1, 2014, Pages

  Antonescu, Cristina ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

angiosarcoma; epithelioid hemangioendothelioma; WWTR1 CAMTA1; YAP1 TFE3

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; INITIATION FACTOR 4E; S6 KINASE; THROMBOSPONDIN 1; VASCULOTROPIN RECEPTOR 3;

ANGIOSARCOMA; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GENETICS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SIZE; CARCINOGENESIS; DIFFERENTIAL DIAGNOSIS; EPITHELIOID CELL HEMANGIOMA; EPITHELIOID HEMANGIOENDOTHELIOMA; EPITHELIOID SARCOMA LIKE HEMANGIOENDOTHELIOMA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEMANGIOENDOTHELIOMA; HEMANGIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT VASCULAR TUMOR; MORPHOLOGICAL TRAIT; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; RADIATION INDUCED NEOPLASM; TUMOR VOLUME; VASCULAR TUMOR; CLINICAL FEATURE; DEMOGRAPHY; EPITHELIOID HEMANGIOMA; MOLECULAR PATHOLOGY;

DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HEMANGIOENDOTHELIOMA, EPITHELIOID; HEMANGIOSARCOMA; HUMANS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891696867     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.176     Document Type: Article

References (47)

1. Brennan MF, Antonescu C, MAKI RG. Management of Soft Tissue Sarcoma. Springer: New York, NY, USA, 2013.
2. Miettinen M. Modern Soft Tissue Pathology: Tumors and Non-Neoplastic Conditions, 1st edn. Cambridge University Press: Cambridge, UK, 2010.
3. Lau K, Massad M, Pollak C, et al. Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. Chest 2011;140:1312-1318.
4. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 1982;50:970-981. (Pubitemid 12047134)
5. Deyrup AT, Tighiouart M, Montag AG, et al. Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases. Am J Surg Pathol 2008;32:924-927.
6. Fletcher CD, Unni K, Mertens F. WHO. Pathology and Genetics. Tumours of Soft Tissue and Bone. IARC Press: Lyon, 2002.
7. Mendlick MR, Nelson M, Pickering D, et al. Translocation t(1;3)(p36.3;q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol 2001;25:684-687. (Pubitemid 32423370)
8. Tanas MR, Sboner A, Oliveira AM, et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med 2011;3: 98ra82.
9. Errani C, Zhang L, Sung YS, et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 2011;50: 644-653.
10. Chan SW, Lim CJ, Chen L, et al. The Hippo pathway in biological control and cancer development. J Cell Physiol 2011;226:928-939.
11. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-2253. (Pubitemid 41697287)
12. Barbashina V, Salazar P, Holland EC, et al. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005;11:1119-1128. (Pubitemid 40175761)
13. Errani C, Sung YS, Zhang L, et al. Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet 2012;205:12-17.
14. Antonescu CR, Le Loarer F, Mosquera JM, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 2013;52:775-784.
15. Mentzel T, Beham A, Calonje E, et al. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol 1997;21:363-374. (Pubitemid 27184768)
16. Contreras AL, Punar M, Tamboli P, et al. Mediastinal germ cell tumors with an angiosarcomatous component: a report of 12 cases. Hum Pathol 2010;41: 832-837.
17. Lipshutz GS, Brennan TV, Warren RS. Thorotrastinduced liver neoplasia: a collective review. J Am Coll Surg 2002;195:713-718. (Pubitemid 35285406)
18. Buchholz TA, Theriault RL, Niland JC, et al. The use of radiation as a component of breast conservation therapy in National Comprehensive Cancer Network Centers. J Clin Oncol 2006;24:361-369. (Pubitemid 46630454)
19. Marion MJ, Boivin-Angele S. Vinyl chloride-specific mutations in humans and animals. IARC Sci Publ 1999;315-324.
20. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer 1948;1:64-81.
21. Al-Abbadi MA, Almasri NM, Al-Quran S, et al. Cytokeratin and epithelial membrane antigen expression in angiosarcomas: an immunohistochemical study of 33 cases. Arch Pathol Lab Med 2007;131: 288-292.
22. Miettinen M, Fetsch JF. Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis. Hum Pathol 2000;31:1062-1067.
23. Folpe AL, Chand EM, Goldblum JR, et al. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol 2001;25:1061-1066. (Pubitemid 32685904)
24. DeYoung BR, Swanson PE, Argenyi ZB, et al. CD31 immunoreactivity in mesenchymal neoplasms of the skin and subcutis: report of 145 cases and review of putative immunohistologic markers of endothelial differentiation. J Cutan Pathol 1995;22:215-222.
25. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H-and Y-antigens-evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994;7:82-90.
26. Miettinen M, Wang ZF, Paetau A, et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 2011;35:432-441.
27. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009;69: 7175-7179.
28. Manner J, Radlwimmer B, Hohenberger P, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 2010;176:34-39.
29. Guo T, Chang NE, Singer S, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 2011;50:25-33.
30. Fernandez AP, Sun Y, Tubbs RR, et al. FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations. J Cutan Pathol 2012;39:234-242.
31. Mentzel T, Schildhaus HU, Palmedo G, et al. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol 2012;25:75-85.
32. Italiano A, Thomas R, Breen M, et al. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosomes Cancer 2012;51: 569-578.
33. Baudino TA, McKay C, Pendeville-Samain H, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002;16:2530-2543.
34. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38:1060-1065. (Pubitemid 44325933)
35. Italiano A, Chen CL, Thomas R, et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer 2012;118: 5878-5887.
36. Donnell RM, Rosen PP, Lieberman PH, et al. Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol 1981;5:629-642.
37. Rosen PP, Kimmel M, Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 1988;62:2145-2151. (Pubitemid 18261853)
38. Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol 2008;32:1896-1904.
39. Meis-Kindblom JM, Kindblom LG. Angiosarcoma of soft tissue: a study of 80 cases. Am J Surg Pathol 1998;22:683-697. (Pubitemid 28280270)
40. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol 2007;18: 2030-2036. (Pubitemid 350286245)
41. O'Connell JX, Nielsen GP, Rosenberg AE. Epithelioid vascular tumors of bone: a review and proposal of a classification scheme. Adv Anat Pathol 2001;8:74-82.
42. Keel SB, Rosenberg AE. Hemorrhagic epithelioid and spindle cell hemangioma: a newly recognized, unique vascular tumor of bone. Cancer 1999;85: 1966-1972. (Pubitemid 29202771)
43. Nielsen GP, Srivastava A, Kattapuram S, et al. Epithelioid hemangioma of bone revisited: a study of 50 cases. Am J Surg Pathol 2009;33:270-277.
44. Errani C, Zhang L, Panicek DM, et al. Epithelioid hemangioma of bone and soft tissue: a reappraisal of a controversial entity. Clin Orthop Relat Res 2012;470:1498-1506.
45. Billings SD, Folpe AL, Weiss SW. Epithelioid sarcomalike hemangioendothelioma. Am J Surg Pathol 2003;27:48-57.
46. Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumor with indolent behavior. Am J Surg Pathol 2011;35:190-201.
47. Trombetta D, Magnusson L, von Steyern FV, et al. Translocation t(7;19)(q22;q13)-a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma Cancer Genet 2011;204:211-215.